CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 7, August 2013
AFRICA
289
16–21.
7.
Vaes B, Delgado V, Bax J,
et al
. Diagnostic accuracy of plasma NT-pro-
BNP levels for excluding cardiac abnormalities in the very elderly.
BMC Geriatrics
2010;
10
: 85.
8.
Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M,
ADHERE scientific advisory committee and investigators. Admission
B-type natriuretic peptide levels and in-hospital mortality in acute
decompensated heart failure.
J Am Coll Cardiol
2007;
49
: 1943–1950.
9.
Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP
and NT-proBNP): measurement and relevance in heart failure.
Vasc
Health Risk Manag
2010;
6
: 411–418.
10. Raizada A, Bhandari S, Khan MA,
et al
. Brain type natriuretic peptide
(BNP) – a marker of new millennium in diagnosis of congestive heart
failure.
Indian J Clin Biochem
2007;
22
(1): 4–9.
11. Latini R, Masson S, Anand I,
et al.
The comparative prognostic value
of plasma neurohormones at baseline in patients with heart failure
enrolled in Val-HeFT.
Eur Heart J
2004;
25
: 292–299.
12. Masson S, Latini R, Arnand IS, Phil D, Barlera S, Angelici L,
et al
. for
the Val-HeFT investigators. Prognostic value of changes in N-terminal
proBNP in Val-HeFT.
J Am Coll Cardiol
2008;
52
: 997–1003.
13. Hartmann F, Packer M, Coats A,
et al
. Prognostic impact of plasma
N-terminal pro-brain natriuretic peptide in severe chronic congestive
heart failure: a substudy of the Carvedilol Prospective Randomized
Cumulative Survival (COPERNICUS) trial.
Circulation
2004;
110
:
1780–1786.
14. Castro LR, Alencar MC, Barbosa MM, Nunes Mdo C, Cardoso JR,
Ribeiro AL. NT-proBNP levels in patients with non-ST-segment eleva-
tion acute coronary syndrome.
Arq Bras Cardiol
2011;
97
(6): 456–461.
15. Januzzi J, Camargo C, Anwaruddin S,
et al
. The N-terminal Pro-BNP
Investigation of Dyspnea in the Emergency Department (PRIDE)
Study.
Am J Cardiol
2005;
95
: 948–954.
16. Booth J, Pinney J, Davenport A. N-terminal pro-BNP – marker of
cardiac dysfunction, fluid overload, or malnutrition in hemodialysis
patients?
Clin J Am Soc Nephrol
2010;
5
: 1036–1040.
17. Baig JA, Alam JM, Ansari MA,
et al
. Evaluation of NT pro BNP of
diagnostic significance in patients with chronic kidney diseases.
Pak J
Biochem Mol Biol
2010;
43
(2): 99–104.
18. David S, Kumpers P, Seidler V,
et al
. Diagnostic value of N-terminal
pro-B-type natriuretic peptide (NT-pro-BNP) for left ventricular
dysfunction in patients with chronic kidney disease stage 5 on haemo-
dialysis.
Nephrol Dial Transplant
2008;
23
: 1370–1377.
19. Van der Horst ICC, de Boer RA, Hillege HL,
et al
. Neurohormonal
profile of patients with heart failure and diabetes.
Netherlands Heart J
2010;
18
(4): 190–196.
20. Andreas M, Zeisler H, Handisurya A,
et al
. N-terminal-pro-brain
natriuretic peptide is decreased in insulin dependent gestational diabe-
tes mellitus: a prospective cohort trial.
Cardiovasc Diabetol
2011;
10
:
28.
21. Wong F. Cirrhotic cardiomyopathy.
Hepatol Int
2009;
3
(1): 294–304.
22. Henriksen JH, Gotze JP, Fuglsang S,
et al
. Increased circulating pro-
brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP)
in patients with cirrhosis: relation to cardiovascular dysfunction and
severity of disease.
Gut
2003;
52
(10): 1511–1517.
23. Kneiseler G, Herzer K, Marggraf G,
et al
. Die Interaktion zwischen
Leber und Herz.
Z Herz-, Thorax- Gefäßchirurgie
2010;
24
(6):
334–340.
24. Gallinat A, Neumann T, Kaiser G,
et al
. Brain natriuretic peptide (BNP):
an early marker of cardiac dysfunction after liver transplantation?
Liver
Outcomes, Supplement to Transplantation
2010;
90
(2S): 1739.
25. Schreiber D, Nix DA, Brown DFM
et al
. Natriuretic peptides in conges-
tive heart failure.
view, updated: Jan 10, 2012 (accessed May 2012).
